Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  15.00 3.22% 481.00 29,663 16:29:56
Bid Price Offer Price High Price Low Price Open Price
481.00 483.00 489.00 472.00 482.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 154.49 -106.40 -12.06 3,500
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:28 UT 527 481.00 GBX

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Investors    Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
21/1/202107:06(Chi-Med)Hutchinson China Meditech Limited2,966
31/7/201806:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201809:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201706:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 16:35:28481.005272,534.87UT
2021-01-22 16:27:43481.003,00314,444.43AT
2021-01-22 16:20:30481.003941,895.14AT
2021-01-22 16:17:32481.004001,924.00AT
2021-01-22 15:44:42483.002921,410.36AT
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 466p.
Hutchison China Meditech Limited has a 4 week average price of 411p and a 12 week average price of 400p.
The 1 year high share price is 538p while the 1 year low share price is currently 250p.
There are currently 727,702,215 shares in issue and the average daily traded volume is 50,283 shares. The market capitalisation of Hutchison China Meditech Limited is £3,500,247,654.15.
steeplejack: Recently,I’ve fortunately benefitted from holding a selection of gene therapy related US biotech stocks.The outperformance of these stocks (whether it is sustained or not)contrasts with the sheer tedium of holding HCM especially in the U.K.,where it is treated like a stock with an inconsequential market cap.In fairness to the AIM marketmakers,the lack of trading interest is more typical of a company with a market capitalisation of around £50m than £3.5bn.It irritates me and I suspect it irritates others.If you were a U.K. institution with a remit to invest in sterling assets,would you really wish to invest sizeably in HCM listed on the AIM market where trading is so obviously thin and illiquid.Of a morning,the shares often open with a 5% nominal spread characteristic of some flighty junior mining company.Well Neil,Woodford might of taken the gamble but HCM should wise up to the fact that outside of NASDAQ ,it’s global listing presence is inadequate and detrimental to the group growing truly global investor recognition.Yawn....
whatja: The press releases always focus on the facts that are agreed by both sides. they leave out the reason for the deal as that might expose weaknesses on both sides. Imagine writing it up as: INmagine has agreed to fund the development of four discoveries that HCM can’t be bothered with and has guaranteed a large profit for HCM on each successful candidate....The chances of success are low for any particular candidate, may still be low for one of four to proceed to approval. Or HCM has a prolific discovery engine but has not invested in its clinical capability and cannot afford to progress all its promising early stage. Significant value has been transferred to a developer in return for no upfront payment and a small unspecified royalty. Not flattering for either side so we get a strategic partnership to develop a portfolio of new candidates. HCM has identified a number of promising drug candidates and its partner is experienced in developing such products implies more likely to be successful. Terms give HCM milestone payments and royalties so generating a future profit stream. Everyone is happy! We need to read between the lines and interpret CHs comments to see what we think drives the deal and therefore whether it is a net gain or loss. I suspect that it does create value from early stage candidates and eases cash flow demands in 22/23/24.
whatja: DBAVFN I think the value is in allowing the pipeline to progress at a higher speed and reducing the cash burn of HCM. Instead of spending several 100m USD on developing this part of the pipeline (ina new area where they are less experienced), they will get up to 230m per candidate plus future royalties. The alternative might be to have a major fund raise to develop these products...which may not be popular either. If HCM has more discoveries than it can handle, it is right to sell them so they can be developed earlier rather than holding them and slowing delivery and being cash constrained. The terms of the contract are likely to be revisited in future as the Lilly and AZ contracts have been....if this is a deal with a small organisation they are taking a lot of risk on, they may need more cash in future which may allow HCM to buy back in if it looks successful.
whatja: Steeplejack, I somewhat agree with you that CKHH is a dead hand on the tiller at the moment. However do not be surprised to see CKHH trade in HCM for a smaller share of something bigger and some is rumoured to be doing that with its Indonesian mobile phone operation, this year it has already forced its oil and gas company into a merger turning a 35% holding to a 20% holding and sold its European mobile towers for 10bn Euro including a 10% stake in the enlarged CEllnex operation. It holds HCM as in it can be sold down when needed. In my view HCM has provided security for the long term plan, it should perhaps stand back a bit more now the company is reaching its own take off speed.
steeplejack: Interesting comments.HCM sometimes comes over as a tad ‘relaxed’;.”Oh well,we don’t need a full LSE listing,yes we’ll do an HK listing when propitious,never fear ...the merits of our drug portfolio will out in due course”.This cool but somewhat casual attitude might come from being inherently confident but also owes something to the fact that HCM is effectively immune to takeover which, it remains,even though the old parent now has a holding below 50%.Ordinarily,a company with this potential would be wondering if a predator wasn’t doing some due diligence and ,if Hutchinson wasn’t ever present in the wings with that substantial equity holding,I think a number of corporate departments would be doing just that on behalf of a number of major players.There certainly appears to be a ‘handbrakeR17; restraining the share price currently.
steeplejack: Hutchison China MediTech (HCM)Last but not least is a $4 billion holding company in China's drug manufacturing sector. Hutchison China MediTech, doing business as Chi-Med, owns a group of subsidiaries engaged in the manufacture and distribution of pharmaceuticals. HCM's products include over the counter medications and consumer healthcare items, as well as sophisticated therapeutics and immunotherapies for the treatment of cancer and autoimmune disorders.As with many pharmaceutical companies, HCM's share price is driven by the company's approved products and development pipeline. In this area, HCM has two advantages.First advantage is Elunate, a drug approved by Chinese regulators as a treatment for colorectal cancer. The company has been working with Eli Lilly, one of the giants of Big Pharma, to fast-track marketing and patient access; earlier this year, that agreement was amended to improve commercialization efforts on Elunate to include all of China.The second advantage is Savolitinib, a drug developed as a treatment for some types of non-small cell lung cancer. The company's New Drug Application (NDA), a key milestone in regulatory approval, has been accepted by China's National Medical Products Administration.Both drugs are being investigated for additional indications, and are part of an active pipeline at the company, which includes nine medications in various stages of development.Among the fans is Deutsche Bank analyst Rajan Sharma who rates HCM a Buy. His $40 price target shows the extent of his confidence, implying ~37% upside for the coming year. (To watch Sharma's track record, click here)Defending his bullish stance on HCM, Sharma writes, "We believe Chi-Med is well on track in its evolution from a Chinese pharmaceutical/OTC company into a fully integrated, innovative global oncology company [...] We see the next steps of Chi-Med's evolution as being approval of its first solely developed drug and launches outside of China, particularly in the US. The company is on track to achieve both of these in the next two years."All in all, HCM has earned a Moderate Buy consensus rating, with 2 Buy reviews in the past three months. Shares are priced at $29.28 and the $40 average price target matches Sharma's. (See HCM stock analysis on TipRanks)
nerdofsteel: indeed miti, let's hope so. I have a very large position here as you know, and I've been extremely disappointed in the share price over the last 4 years - I could have made a lot of money investing in my other favorites - Beigene, Genmab and Juno so my loyalty to the company has cost me dearly. I hope 2021 will reverse that. I always get perplexed when I look at Beigene, how it grew so quickly by striking deals with other big pharma etc We seem to be very (too) conservative and lack innovation on the corporate side. For example, given our distribution and sales channels in China, why haven't we leveraged that to in-licence and resell blockbusters like Beigene did with Celgene? That would have allowed us to ramp up the sales channel and get significant financial uplifts whilst still developing our own pipeline. Chi-Med seem to have the view they want to focus on their own innovation but why not have parallel growth strategies. If the share price is still in the 400's by the end of 2021 I will have to invest elsewhere. I hope that is not the case.
miti 1000: Having sold out at the highs of 550 a few years back when MSCI china funds had to buy the stock, I thought I'd revisit hcm. Long term posters(Matt) moan about moving the listing (FFS, its already on 2 indices!!Get a grip, man) and others simply just chose to ignore Savo/Tagrisso and the lack of an interim readout. Despite the huge bullishness on here , lets be honest, Savolitinib which is what controls the share price has just not progressed as the company wished( remember it failed in one indication 3 years ago) but luckily , the share price rose cos of the aforementioned fund buying allowing me a great exit. There has been been no interim readout of data in combination with Tagrisso.In fact, it has now been called an 'Internal' readout so clearly there appears to be issues in the poster child killer application and indicates things are not progressing to plan . I presume they will have to come out with proper details in 2021 and either the share price will halve or it will go thru the roof if it works after tweaks. This explains why the share price ash gone nowhere but lower since I sold despite such huge gains elsewhere in the sector. I made a huge gain last time on HCM but I'm just not tempted this time even after a 30% fall since I sold almost 3 years. Hard to invest in big size on such a binary bet when the signs don't seem promising on savo/tagrisso.
its the oxman: It's been a miserable few years for hcm relative to the market. Anyone got predictions for the share price at the end of 2021. I reckon 585p. We have plenty of catching up to do.
dbadvn: HCM share price , lacking the ridiculous hype surrounding other biotechs, and any takeover premium , will follow the numbers. It will start to rocket as soon as the market sees the cash being thrown off in the next few years as sales rise rapidly.
Hutchison China Meditech share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 08:52:59